sugemalimab
cstone pharmaceuticals
['lymsm', 'sugemalimab']
next up: results of phase ii trial of anti-pd-l1 sugemalimab in r/r enktl. orr 50%, median dor and os not reached. impressive in a disease with dismal prognosis. would love to see combos with other active agents (hypomethylating, hdaci). #asco22 #lymsm 
Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ??????